Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of sofosbuvir/ledipasvir plus ribavirin in HCV genotype 1 and HIV co-infected, NS3/4A PI-experienced patients
2013-002607-33Phase 2Active
- Sponsor
- ANRS
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ledipasvir and ribavirin in chronic hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by ANRS. Primary endpoint: Sustained virological response at 12 weeks post-treatment (SVR12). Started Jun 2015; status: active.
02
Drugs
ledipasvirribavirin
03
Conditions
chronic hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-002607-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002607-33.